Mostrar el registro sencillo del ítem

dc.contributor.authorCaponcello, Maria Giulia
dc.contributor.authorMacías Sánchez, Maria del Mar
dc.contributor.authorMacías, Juan
dc.contributor.authorAguilar Guisado, Manuela
dc.contributor.authorRomero Palacios, Alberto 
dc.contributor.authorRetamar Gentil, Pilar
dc.contributor.authorMárquez-Gómez, Ignacio
dc.contributor.authorMartínez-Marcos, Francisco Javier
dc.contributor.authorLópez Cardenas, Salvador 
dc.contributor.authorMarrugal Lorenzo, Jose Antonio
dc.contributor.authorQuijano Ruiz, Blanca
dc.contributor.authorMata, Rosario
dc.contributor.authorCarmona Sánchez, Gloria
dc.contributor.authorOyonarte, Salvador
dc.contributor.authorRodríguez Baño, Jesús
dc.contributor.otherCirugíaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2026-11-11T11:08:37Z
dc.date.available2026-11-11T11:08:37Z
dc.date.issued2026-03-31
dc.identifier.issn1578-1852
dc.identifier.issn0213-005X
dc.identifier.urihttp://hdl.handle.net/10498/40626
dc.description.abstractIntroduction: A phase 2 trial was conducted to evaluate the safety and efficacy of convalescent plasma (CP) for patients admitted with COVID-19 in the pre-vaccine era. Methods: CP was compared to standard of care (SoC) in a randomized clinical trial in patients admitted with COVID-19 pneumonia and with either hypoxia and/or some underlying condition from April to December 2020 in 15 hospitals in Andalusia, Spain. The primary endpoints were adverse events and failure (all-cause death and need for mechanical ventilation during the first 21 days). Result: The procedure for CP was developed and worked properly. Overall, 72 patients of 88 evaluated were recruited (37 and 35) assigned to CP and SoC. Median duration of COVID-19 related symptoms was 7 and 6 days, and median oxygen saturation at randomization was 93% and 92.5% in experimental and control arms, respectively. Overall, 8 (21.6%) patients in the experimental CP group (non related to CP) and 8 (22.9%) in the control group developed grade 3 adverse events (relative risk [RR] 0.94; 95% CI: 0.39–2.24); failure occurred in 3 (8.1%) and 4 (11.4%) patients, respectively ([RR] 0.94, CI: 0.14–6.35 for both events). No differences in secondary endpoints (change in inflammatory parameters, negativization of SARS-CoV-2 PCR or duration of hospital stay) were found. Conclusions: The results suggested that CP is safe for use in COVID-19 patients, although no significant efficacy signal could be observed. A successful regional system for CP administration was developed.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherELSEVIERes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.sourceEnfermedades Infecciosas y Microbiologia Clinica, Vol. 44, Núm. 6, 2026es_ES
dc.subjectCOVID-19es_ES
dc.subjectConvalescent plasmaes_ES
dc.subjectClinical triales_ES
dc.titleSafety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID)es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/J.EIMC.2026.503166
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional